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Introduction 
Hypertensive disorders are the most common medical complications of pregnancy and are 
a major cause of maternal and neonatal morbidity and mortality worldwide 
(Witlin and Sibai, 1997) and ranges from 0.05% to 27% in developed and undeveloped 
countries, respectively (Kaunitz et al., 1990; Duley, 1992; Moodley and Daya, 1993). At 
King Edward VIII Hospital (KEH), a large urban referral centre serving an 
underprivileged Black community of Durban, South Africa, 18% of all admissions to the 
Obstetric Unit have some degree of hypertension (Moodley, 1999). This data is hospital­
based and may not be representative of the population as a whole. The shortage of medical 
and skilled nursing staff together with inadequate antenatal facilities and care, account for 
the high incidence of pre-eclampsia in developing countries (Crowther, 1985). 
The pathophysiology of pre-eclampsia 1s well understood even though the aetiology 
remains obscure. It is believed to be: 
(1) primarily a trophoblastic disease (Zuspan, 1991 ),
(2) the result of the placental production of lipid peroxides due to a possible
oxidant/antioxidant imbalance (Wang et al., 1992a),
(3) an endothelial cell disorder (Rodgers et al., 1988), and
( 4) associated with an imbalance in the prostacyclin/thromboxane ratio
(Wang et al., 1991a).
There exists the potential for daily dietary exposure to fumonisins and other mycotoxins in 
maize and maize-based foods, a staple of the diet of much of the black population of South 
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Africa, as well as through the use of herbal medicines, the ingredients of which are also 
prone to fungal contamination. The unusually high incidence of pre-eclampsia among 
black African women admitted to KEH prompted the present study into the possible role 
that fumonisin B1 (FB1) may play in the pathophysiology of this disorder. 
1.1 OBJECTIVES 
The objectives of this study were: 
l. to immunolocalise FB 1 in pre-eclamptic placental tissue,




2.1 HYPERTENSION IN PREGNANCY 
Hypertension may be induced by pregnancy, coincide with, or be exacerbated by it. The 
lack of agreement on the classification and definition of hypertensive disorders in 
pregnancy is due to the limited knowledge of the precise nature and cause of the disorders, 
the absence of clinical or pathological features or tests by which they can clearly be 
separated, and the need for an agreed nomenclature (Davey and MacGillivray, 1988). One 
of the best classifications available at present is that of the American College of 
Obstetricians and Gynaecologists, which is outlined in Table 2.1. 
Table 2.1: Hypertensive disorders of pregnancy. 
Gestational Hypertension Hypertension developing during pregnancy after 20 
(Pregnancy-induced Hypertension) weeks' gestation or in the first 24hrs post-delivery 
without gross oedema or proteinuria and returning to 
normotension within ten days after delivery. 
Pre-eclampsia/Eclampsia Hypertension associated with proteinuria and/or 
oedema. Eclampsia refers to the onset of 
convulsions, with signs and symptoms of 
pre-eclampsia, during pregnancy, labour, or 
within seven days of delivery in the absence of 
epilepsy or another condition predisposing to 
convulsions. 
Chronic Hypertension Hypertension developing before 20 weeks' gestation 
and persisting for more than six weeks following 
delivery. 
Superimposed Pre-eclampsia Development of pre-eclampsia, or eclampsia, in 
patients with diagnosed chronic hypertension. 
2.2 PRE-ECLAMPSIA 
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Pre-eclampsia is a disease peculiar only to human pregnancy (Zuspan, 1987). It is a 
multisystem disorder of unknown aetiology and almost invariably occurs after 34 weeks of 
gestation (Williams and de Swiet, 1997) (Fig. 2.1 ). Pre-eclampsia is a progressive disease 
with a variable mode of presentation and rate of progression. It is clinically defined by 
hypertension, proteinuria and oedema (Redman and Jefferies, 1988). 
Hypertension in pre-eclampsia is defined as systolic blood pressure ;?: l 40mmHg and/or a 
diastolic blood pressure 2 90mmHg, or an increase in systolic blood pressure 2 30mmHg 
or an increase in diastolic blood pressure 2 1 SmmHg from pre-pregnancy or first trimester 
blood pressure recordings confirmed by two readings at least six hours apart (Witlin and 
Sibai, 1997). The proteinuria of pre-eclampsia is defined as the excretion of 2 300mg 
protein during a 24 hour period or ''2+" dipstick testing if 24 hour urine collection is not 
possible. Oedema is often not included in the definition of pre-eclampsia as moderate 
degrees of oedema may be detected in 80% of normotensive pregnant women, most of 
whom are healthy. Pathological oedema affects 85% of women with proteinuric 
pre-eclampsia and usually involves the face, hands, and feet. Such oedema appears 
relatively suddenly and is associated with accelerated weight gain (Sibai, 1990). 
The disease may also be associated with abnormalities of the central nervous system 
(Redman, 1990), thrombocytopaenia, hyperuricaemia, abnormal liver tests, haemo­
concentration, hypoalbuminaemia, and eclampsia (Moodley, 1997). 
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If a patient with pre-eclampsia develops convulsions, the patient is said to have eclampsia. 
This is a life-threatening complication of pregnancy. Various premonitory symptoms and 
signs, such as headache, epigastric pain, and hyper-reflexia usually precede eclampsia. 
The seizures are attributed to platelet thrombi that obstruct the cerebral microcirculation or 
to intense, sometimes localised vasoconstriction (Sibai, 1986). Eclampsia complicates 
approximately 1 :2 000 deliveries in Europe and from 1: 100 to 1: 1 700 deliveries in 
developing countries (The Eclampsia Trial Collaborative Group, 1995). 
Pre-eclampsia progresses from a pre-clinical stage, through a symptomless clinical phase 
in the second half of pregnancy, to several possible crises. The maternal complications of 
pre-eclampsia are presented in Table 2.2. Foetal complications include pre-maturity, 
growth retardation, stillbirth, and neonatal death. Maternal mortality varies from 0-27% 
while the incidence of foetal mortality varies from 20-30% (Zuspan, 1984). Data on 
maternal mortality from developing countries is scarce and mostly hospital-based. 
Maternal mortality from hypertension in the black population of Durban accounts for 32% 
of deaths (Moodley and Rout, 1997). 
2.2.l Early onset pre-eclampsia 
Early onset pre-eclampsia is characterised by severe hypertension, proteinuria, and/or 
oedema occurring early in pregnancy, specifically between 24 and 34 weeks of gestation. 
It tends to recur in subsequent pregnancies and has a higher foetal mortality and maternal 
morbidity than that of idiopathic pre-eclampsia (Ihle et al., 1987; Druzin, 1988). In 
addition, early onset pre-eclampsia is associated with underlying renal disease 
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(Lindheimer and Chesley, 1987; Weiner and Bonsip, 1990). Renal abnormalities were 
found in 67% of primiparous women and 63% of multiparous women (Ihle et al., 1987). 
Table 2.2: Maternal complications of pre-eclampsia. 




Renal system Renal cortical necrosis 
Renal tubular necrosis 
Respiratory system Laryngeal oedema 
Pulmonary oedema 
Hepatic system Jaundice 
Hepatic rupture 
Coagulation system Disseminated intravascular coagulation 
Microangiopathic haemolysis 
Placenta Placental infarction 
Abruptio placentae 
2.2.2 Predisposing factors to pre-eclampsia 
The risk of pre-eclampsia is increased in certain subsets of women, including those 
women at the extremes of their reproductive ages, i.e., under 20 and over 3 5 years of age 
(Gant and Worley, 1980), low socio-economic status, multiple gestation, and women with 
medical or obstetric complications such as the presence of a hydatiform mole, 
polyhydramnios, non-immune foetal hydrops, diabetes, chronic hypertension, and 
underlying renal disease. Pre-eclampsia in a past pregnancy also increases the risk of 
recurrent disease (Caritis et al., 1998). Larrabee and Monga (1997) demonstrated that 
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sickle cell trait-positive women have an increased risk of pre-eclampsia, the 
pathophysiological mechanisms of which remain to be elucidated. A racial difference in 
the incidence of pre-eclampsia/eclampsia has also been observed (Magee, l 96 l; 
Caritis et al., 1998). 
Susceptibility to pre-eclampsia has a strong genetic component. The incidence in mothers, 
daughters, sisters, and grand-daughters is two- to five-fold higher than in mothers-in-law, 
daughters-in-law, and control populations (Cooper et al., 1993). A primigravida is eight 
times more likely to develop pre-eclampsia if her sister had the condition and four times 
more likely if her mother was affected (O'Brien, 1990). This familial tendency may be due 
to an autosomal recessive trait (Rao and Ramkumar, 199 l ). 
Change of sexual partners appears to increase the risk of pre-eclampsia in subsequent 
pregnancies (Feeney and Scott, 1980; Campbell et al., 1985). There is growing evidence 
that the longer the exposure to paternal seminal f uid before conception, the less the risk of 
pre-eclampsia and pregnancy-induced hypertension (Robillard et al., 1994). Antigens 
within seminal fluid cross-react with trophoblastic antigens. Repeated exposure to seminal 
fluid of one partner may build up allogenic recognition. This may protect against 
trophoblast-lymphocyte reactions that could be responsible for poor placentation in 
women who go on to develop pre-eclampsia (Kajino et al., 1988). 
2.3 PATHOPHYSIOLOGY OF PRE-ECLAMPSIA 
Pre-eclampsia is a syndrome that affects virtually all maternal organ systems (Fig. 2.2). 
The underlying pathophysiology is still not fully elucidated but the common pathological 

feature in the placenta, kidneys and brain is vascular endothelial damage and dysfunction, 
and the major pathological changes are in the placental bed (Moodley, 1997). 
2.3.1 The trophoblast 
In normal pregnancy, placental trophoblastic cells migrate into the maternal spiral arteries 
displacing their muscular endothelium. The transformation of the spiral arteries in the 
placental bed to uteroplacental arteries occurs in two phases. The first phase affects the 
decidual portions and the second phase affects the myometrial portions of the arteries 
which become dilated (Robertson et al., 1986). These changes transform the vascular 
supply to a low pressure and high flow system to meet the needs of the foetus and the 
placenta (Moodley, 1997). 
Trophoblastic invasion is abnormally shallow in pre-eclampsia. Indeed pre-eclampsia is 
associated with failure of or incomplete trophoblastic invasion of the spiral arteries 
(Boyd and Hamilton, 1970). Two types of abnormal invasion are observed in 
pre-eclampsia: 
1. Trophoblast invasion of the uterine parenchyma is uniformly shallow and invasion
of the vasculature does not proceed beyond the decidual portions of the spiral
arteries. As a result the maternal vessels do not undergo the complete spectrum of
physiological changes observed in normal pregnancy (Brosens et al., 1972;
Gerretsen et al., 1981) (Fig. 2.3).
2. The number of vessels that show evidence of trophoblast invasion is decreased
(Khong et al., 1986).
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The mature placenta (normotensive or pre-eclamptic) is made up of villous trees. Each 
villous tree can be subdivided into segments that differ mainly as to stromal structure, 
vessel structure, and position within the villous tree. The following villous types have been 
described (Fig. 2.4): 
• Stem villi are characterised by a condensed fibrous stroma, arteries and vems or
arterioles and venules.
• Intermediate villi are long, slender, peripheral subdivisions characterised by the
absence of vessels.
• Terminal villi are the final, grape-like segments of the mature intermediate villi,
characterised by their high degree of capillarisation and the presence of highly dilated
sinusoids. They represent the main sites of foetomatemal exchange.

2.3.2 Lipid peroxidation in pregnancy 
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Lipid peroxidation is a process that normally occurs at low levels in all cells and tissues. 
Maternal blood levels of lipid peroxides are significantly elevated in pre-eclampsia 
relative to normal pregnancy (Wang et al., 1991 b; Uotila et al., 1993). Placental tissue 
levels and production rates of lipid peroxides are also abnormally increased in 
pre-eclampsia (Wang et al., 1992a). Rodgers et al., (1988) reported that pre-eclamptic sera 
contain "cytotoxic factors" that damage endothelial cells. The identity of these cytotoxic 
factors is not yet known, but lipid peroxides are likely candidates as suggested by 
Hubel et al., (1989). Lipid peroxides that are formed in placental tissue may accumulate in 
lipoproteins which are stable enough to function as circulating compounds as they have a 
half-life of three hours (Gorog, 1991). These lipoproteins may be transported through the 
circulation to propagate further lipid peroxidation at sites distal to areas of initial damage 
(Hubel et al., 1989). 
Lipid peroxides are formed when polyunsaturated fatty acids interact with free radicals 
such as oxygen free radicals which include: superoxide radical ( •02-), hydroxyl radical 
( •OH), alkoxyl radical (LO.), peroxyl radical (LOO.), singlet oxygen (
1
02), and nitric
oxide (NO.), as well as others. Lipid peroxidation is a process whereby oxygen free 
radicals attack the double bonds of polyunsaturated fatty acid side chains in placental 
phospholipid membranes. These fatty acids are then converted to lipid peroxides 
(Walsh, 1994). 
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Lipid peroxides and oxygen free radicals stimulate peroxidation reactions that are toxic to 
cells and cell membranes. Some of their effects include: 
• Endothelial cell injury and dysfunction (Hennig and Chow, 1988),
• Alterations in membrane fluidity (Halliwell and Gutteridge, 1990),
• Altered membrane permeability to ions and proteins (Rice-Evans and Burdon, 1993),
• Enhanced adhesion and activation of neutrophils (Haeger et al., 1992),
• Platelet aggregation (Shatos et al., 1991 ),
• Increased uptake oflow-density lipoproteins into the vessel wall
(Hennig and Chow, 1988),
• Stimulation of mitogens and growth factors (Rice-Evans and Burdon, 1993),
• Decreased protein synthesis (Machlin and Bendich, 1987),
• Modification and destruction of proteins (Rice-Evans and Burton, 1993),
• DNA strand breakage (Floyd, 1990),
• Increased production of toxic aldehydes (Walsh, 1994),
• Inactivation of enzymes (Walsh, 1994), and
• Increased intracellular calcium leading to the activation of calcium-dependent enzymes
such as proteases and phospholipases (Walsh, 1994).
Another possible mechanism for the generation of lipid peroxides in the circulation 
involves the activation of neutrophils. Activated neutrophils generate superoxide anions in 
women with pre-eclampsia (Greer et al., 1989; Tsukimori et al., 1993). Neutrophil 
activation is confined to the maternal circulation (Greer et al., 1991) and could be 
activated as they circulate through the intervillous space by lipid peroxides generated by 
the trophoblastic cells (Wang et al., 1992b ). A recent investigation has shown that the 
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content of lipids, cholesterol and lipid peroxides is elevated in decidua basalis tissues of 
women with pre-eclampsia and may be a source of lipid compounds that cause maternal 
endothelial dysfunction (Staff et al., 1999). 
Antioxidants oppose the toxic actions of lipid peroxides and oxygen free radicals, and they 
limit the amount of lipid peroxides that are formed. Antioxidants are derived either from 
endogenous synthesis ( e.g., superoxide dismutase, catalase, and glutathione peroxidase) or 
from the diet (e.g., vitamins E and C). Antioxidants are present in cells and in extracellular 
fluids (Walsh, 1994). 
In contrast to lipid peroxides, the net antioxidant activity in maternal blood is significantly 
decreased in pre-eclampsia as compared to normal pregnancy (Wisdom et al., 1991; 
Wang et al., 1991a; Davidge et al., 1992). Defciency of vitamin E in pre-eclampsia is 
especially important because it is a lipid-soluble vitamin that becomes a constituent of the 
lipid bilayer of cell membranes. Vitamin E stabilises biological membranes and protects 
them from oxidative damage. Vitamin E acts as a free radical scavenger to prevent lipid 
peroxidation of membranes. In situations of vitamin E deficiency, there is widespread 
derangement of cell membranes resulting from lipid peroxidation (Walsh, 1994). There is 
conflicting evidence as to the concentration of vitamin E in maternal blood of women with 
pre-eclampsia. Some investigators have found a decreased concentration of vitamin E in 
the maternal blood of women with severe pre-eclampsia, as compared with normal 
pregnancy (Wang et al., 1991a; Mikhail et al., 1994). Vitamin E is consumed when 
exerting its antioxidant activity. Abnormal increases in lipid peroxides in pre-eclampsia 
could increase consumption, resulting in the decreased vitamin E levels observed. Another 
possibility for these decreased levels of vitamin E could be a decrease in the absorption of 
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vitamin E from the gut as a result of the vasoconstriction of pre-eclampsia 
(Wang et al., 1991a). Schiff et al. (1996) demonstrated that women with pre-eclampsia 
had elevated vitamin E plasma concentrations compared to normal pregnancy. This 
finding agrees with those of Uotila et al. (1993). Schiff et al. (1996) also demonstrated 
increasing plasma vitamin E concentrations with increasing severity of disease and 
speculated that the increment in plasma vitamin E concentrations could reflect a 
compensatory response to primary oxidative stress, which characterises the pre-eclamptic 
process. 
Wang et al. (1991 a) hypothesised that in pre-eclampsia not only is there an imbalance 
between lipid peroxides and/or decreased antioxidants, there is also an imbalance between 
thromboxane and prostacyclin. These prostaglandins are synthesised from arachidonic 
acid in the platelets, blood vessel walls and the decidua especially in the uteroplacental 
area (Moodley, 1997). Prostacyclin is a potent vasodilator, an inhibitor of platelet 
aggregation, and an inhibitor of uterine contractility. Its combined actions lead to an 
increase in uteroplacental blood flow in normal pregnancy. Thromboxane is a potent 
vasoconstrictor, a stimulator of platelet aggregation, and a stimulator of uterine 
contractility. Its combined actions lead to a decrease in uteroplacental blood flow. In 
normal pregnancy the concentration ratio of prostacyclin to thromboxane in maternal 
blood progressively favours prostacyclin as pregnancy advances (Wang et al., 1991 b ). In 
pre-eclampsia there is an imbalance between thromboxane and prostacyclin that favours 
the actions of thromboxane (Walsh, 1985). 
Wang et al. (1992a) speculated that abnormally increased levels of lipid peroxides m 
pre-eclampsia inhibit prostacyclin synthase to decrease prostacyclin synthesis. 
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(Flavahan and Vanhoutte, 1995). These features are found in pre-eclampsia and suggest 
that the maternal syndrome is, at least in part, an endothelial disorder (Roberts and 
Redman, 1993). Evidence of endothelial cell damage prior to the clinical manifestation of 
pre-eclampsia can be demonstrated by the presence of markers of endothelial cell 
activation. Specifically, levels offibrinectin (Ballegeer et al., 1989) and factor VIII-related 
antigen are elevated (Roberts and Redman, 1993). Furthermore, women with endothelial 
cell damage, secondary to pre-existing hypertension, or other microvascular disease, have 
a higher incidence of pre-eclampsia than normotensive women (Roberts and Redman, 
1993). 
Lipid peroxides enhance vasoconstriction and responsiveness of the systemic vasculature 
to vasoconstrictors. Therefore circulating lipid peroxides may contribute directly to 
maternal hypertension or through their ability to inhibit prostacyclin synthase 
(Walsh, 1994). 
In addition to maternal hypertension and reduced uteroplacental blood flow, two other 
primary features of pre-eclampsia are proteinuria and oedema. In this regard, lipid 
peroxides alter cell membrane permeability to hydrogen and other 10ns 
(Halliwell and Gutteridge, 1990), and the superoxide anion increases capillary 
permeability to proteins (Granger et al., 1981 ). Damage to the endothelial cell membranes 
in the glomerulus of the kidney by lipid peroxides could explain proteinuria. Increased 
permeability to proteins of endothelial cell membranes in the systemic circulation could 
explain oedema (Walsh, 1994). 
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2.3.4 Renin-angiotensin-aldosterone system 
The renin-angiotensin-aldosterone system is a finely tuned homeostatic mechanism that 
regulates a variety of body functions, including blood pressure and extracellular fluid 
volume. The generation of angiotensin II results from a series of specific enzymatic 
cleavages of a polypeptide precursor. The process begins when the enzyme renin acts 
upon a circulating glycoprotein, angiotensinogen (renin substrate), to produce the 
decapeptide angiotensin I. Converting enzyme then removes the two carboxyl-terminal 
peptides to form angiotensin II (Carr and Gant, 1983). 
Angiotensin II is an octapeptide that acts directly on vasculature to produce 
vasoconstriction and upon the zona glomerulosa of the adrenal cortex to stimulate the 
release of aldosterone. Aldosterone increases sodium concentration and blood volume, 
which in tum increases blood pressure. The entire renin-angiotensin-aldosterone system is 
stimulated by pregnancy (Carr and Gant, 1983). 
Langer et al. (1998) evaluated the activity of the renin-angiotensin-aldosterone system 
during normotensive and pre-eclamptic pregnancy with the specific measurement of 
angiotensin II, the effector of this hormonal system. Their results showed that as early as 
the first trimester of normal pregnancy, active renin concentration reached a high value 
.and then remained stable, whereas angiotensin I, angiotensin II, and aldosterone remained 
at a level comparable to the postpartum values. Highest activity of the renin-angiotensin­
aldosterone system were observed during the third trimester with increased levels of 
angiotensin I, angiotensin II, and aldosterone. 
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In contrast, in patients with pre-eclampsia, despite a slight increase in active renin levels, 
the other parameters of the renin-angiotensin-aldosterone system were low compared with 
the third trimester of normal pregnancy and were comparable to postpartum data 
(Langer et al., 1998). This could contribute to the diminished haemodynamic control 
observed in women developing pre-eclampsia (August et al., 1995; Langer et al., 1998). 
Blood vessels in pre-eclamptic mothers demonstrate increased capillary permeability with 
exaggerated responses to angiotensin II, a powerful vasoconstrictor which plays a role in 
the control of salt and water balance (De Jong et al., 1991 ). The insensitivity to 
angiotensin II seen in normal pregnancy can be abolished by treatment with a 
cyclo-oxygenase inhibitor such as indomethacin (Broughton-Pipkin et al., 1989). These 
experiments demonstrate that in normal pregnancy, angiotensin II might be balanced by 
the action of vasopressor prostaglandins such as prostacyclin. A deficiency of prostacyclin 
might therefore result in the angiotensin II sensitivity seen in pre-eclampsia. This 
deficiency of prostacyclin could be due to endothelial dysfunction caused by lipid 
peroxides and is likely to contribute to enhanced platelet reactivity and vascular damage 
(Lyall and Greer, 1994). 
2.4 FUMONISINS 
Mycotoxins are a diverse group of secondary metabolites produced by a wide range of 
fungi on foods and feeds (Coulombe, 1993). These secondary metabolites have the 
potential to produce severe adverse human and animal health effects upon ingestion, 
inhalation, or skin contact (Miller, 1991 ). 
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The fungus Fusarium moniliforme Sheldon is one of the most prevalent seed-borne fungi 
associated with maize (Zea mays L) intended for human and animal consumption 
worldwide (Marasas et al., 1984). This fungus is frequently found in temperate subtropical 
and intermediate areas of South Africa (Smith and Moss, 1985). Fusarium moniliforme is 
associated with disease at all stages of maize plant development, infecting the roots, stalk, 
and kernels (Munkvold and Desjardins, 1997). There is also evidence of post-harvest 
decay of grains by F moniliforme (Diaz and Boermans, 1994 ). This fungus is not only the 
most common pathogen of maize, it is also among the most common fungi found 
colonising symptomless maize plants. It is an almost constant companion of maize plants 
and seed. In many cases, its presence is ignored because it seems not to cause visible 
damage. Symptomless infection can exist throughout the plant, and seed-transmitted 
strains of the fungus can develop systemically to infect the kernels (Kedera et al., 1992; 
Munkvold et al., 1997). 
Fumonisins are the toxic secondary metabolites produced by F moniliforme, 
F proliferatum and F nygamai. They are produced by these fungi on maize, in culture 
and under natural conditions (Alberts et al., 1990). 
2.4.1 Characteristics of fumonisins 
The fumonisins are a group of related, strongly polar compounds. They are soluble in 
polar solvents ( e.g., water, methanol and acetonitrile ), but are insoluble in organic solvents 
(Diaz and Boermans, 1994 ). Fumonisins are also heat stable and therefore a potential risk 
to humans (Alberts et al., 1990). Their structures are based on a long hydroxylated 
hydrocarbon chain (pentahydroxyeicosane) with two propane tricarboxylic acid moieties 

2.4.2 Occurrence of fumonisin B1 in the environment 
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Sydenham et al. (1990) made the first conclusive report of FB 1 in homegrown maize 
obtained from a high oesophageal cancer (QC) risk area of the Transkei, southern Africa. 
Fumonisin B1 levels detected in 38 samples of "good" homegrown maize which is used as 
the staple diet in the Transkei, ranged from 0-7.9µg/g. Fumonisin B 1 levels detected in 37 
samples of "mouldy" homegrown maize which is used mostly for beer brewing, ranged 
from 0. l l-l l 7.5µg/g (Rheeder el al., 1992; Sydenham et al., 1990). Even higher levels of 
FB1 (up to 155µg/g) have been reported in homegrown maize from a high-incidence area 
ofOC in China (Chu and Li, 1994). 
Fumonisin levels in 182 commercial human foods from three countries, i.e., South Africa 
(Sydenham el al., 1991 ), Switzerland (Pittet et al., 1992), and the USA 
(Sydenham et al., 1991), ranged from 0-2.8µg/g. Fumonisins have also been found in 
maize-based human foodstuffs from other countries in Africa ( e.g., Botswana, Egypt, 
Kenya and Zimbabwe) as well as outside of Africa. There is little available data regarding 
the incidence of pre-eclampsia in Africa as women, particularly in rural communities, 
have limited access to health services. As a result reports of pre-eclampsia cannot be 
regarded as accurate as the incidence is often under-reported. However, pre-eclampsia is 
believed to be prevalent in developing African countries such as Botswana, Egypt, Ghana, 
South Africa, Swaziland, Tanzania, Uganda, Zimbabwe and Zaire, where maternal 
mortality due to pre-eclampsia/eclampsia is relatively high (10-27%) (Duley, 1992). In the 
South African context, district hospitals in Hlabisa and Eshowe have reported a high 
incidence of pre-eclampsia (Drysdale, 1999; McDonald, 1999). Many of the above­
mentioned developing countries report a high incidence of fungi-contamination of maize 
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and maize products. Table 2.3 provides further examples of the occurrence of FB 1 m 
maize in different countries. 
Table 2.3: Occurrence of FB1 in maize in different countries (Dutton, 1996). 



































2000 Svdenham et al., 1993 
38 500 Sydenham et al., 1992a 
2310 Doko et al., 1995 
50 Sydenham et al., 1991 
1732 Yoshizawa et al., 1994 
70 Doko et al., 1995 
2380 Svdenham et al., 1991 
50 000 Le Bars & Le Bars, 1995 
6555 Julian et al., 1995 
334 000 Fazekas & Tothe, 1995 
5310 Doko et al., 1995 
2600 Ueno et al., 1993 
1327 Soo et al., 1994 
4600 Ueno et al., 1993 
660 Svdenham et al., 1991 
30 Doko et al., 1995 
3450 Doko et al., 1995 
30 Doko et al., 1995 
250 000 Bottalico et al., 1995 
1890 Sydenham et al., 1994 
7100 Rheeder et al., 1995 
80 Sanchis et al., 1994 
790 Pittet et al., 1992 
350 Trucksess et al., 1995 
1048 Sydenham et al., 1991 
321 Chamberlain et al., 1993 
37 900 Murphy et al., 1993 
1410 Hopmans & Murphy, 1993 
1710 Doko et al., 1995 
2.4.3 Toxicological affects of fumonisin B1
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It is the polarity of the compound that determines its level of carcinogenicity 
(Gelderblom et al., 1993), i.e., the more polar a molecule, the greater the cytotoxic 
response. In addition to polarity, the presence of a free amino group and the location of the 
hydroxyl group could also affect the biological activity of these compounds. Thus, both 
the amino group and intact molecule play an important role in the toxic and cancer 
promoting activity of fumonisins. This would explain the association of FB1 with soluble 
and insoluble portions of the cell (Cawood et al., 1994). 
Fumonisin B1 is poorly absorbed and rapidly excreted from the gastrointestinal tract 
(GIT), leading to low plasma levels (Prelusky et al., 1994 ). In rats it mainly passes straight 
through the GIT and what is absorbed 1s mainly excreted m the bile 
(Shephard et al., 1994a). The uptake of FB1 is very small in all animal models and there is 
no evidence to suggest that it is any different in humans (Dutton, 1996). Either the toxin is 
highly potent or its absorption is aided by other dietary factors, such as alcohol or fat. It is 
unlikely that FB1 is modified into a more accessible form (e.g., by esterification), or that 
there are transport systems that assist its passage, either present in an active or latent form 
(Dutton, 1996). In their experiments with a horse given FB1 by gavage or intraperitoneal 
(i.p.) injection, Laurent et al. (1989) concluded that other factors assisted absorption from 
the stomach during digestion. The question of absorption of FB1 from the GIT has not 
been resolved. 
Many animals develop liver and kidney damage after consumption of FB1 and a few 
manifest severe neurotoxicity (equids) or pulmonary oedema (pigs) (Bucci et al., 1998; 
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Marasas, 1994). It 1s also hepatocarcinogenic (Gelderblom et al., 1988; 
Gelderblom et al., 1991; Riley et al., 1994 ). Fumonisin B 1 increases the "leakiness" of the 
permeability barrier of endothelial cells (Ramasamy et al., 1995) and is both 
immunostimulatory and immunosuppressive (Martinova and Merrill, 1995). The 
pathogenesis of FB1 poisoning, therefore, may involve widespread disruption of cellular 
function. 
Epidemiological studies in South Africa and China have shown that there is a relationship 
between consumption of maize containing high levels of FB 1 and QC 
(Rheeder et al., 1992; Chu and Li, 1994 ). Concern about the relationship between 
fumonisin consumption and developmental and reproductive effects arose from the 
observation of stillbirths, abortions and reduced conception rates in pregnant sows fed 
fumonisin-contaminated diets (Harrison et al., 1990; Bane et al., 1992). In some areas of 
Africa and China, a high incidence of neural tube defects has been reported in areas where 
high rates of OC has been seen (Viljoen et al., 1995). Health authorities in Texas have also 
indicated a possible relationship between maize consumption and a cluster of neural tube 
defects in Cameron County (Texas Department of Health, I 992). Supplementation with 
folic acid has been shown to reduce the incidence of neural tube defects (Oakley et al., 
1994) however, there is evidence that neural tube defects in some populations are 
unrelated to daily intake of folic acid (Shaw et al., 1995). Several in vitro and in vivo 
studies have indicated that FB1 affects embryonic development (Floss et al., 1994; 
Lebepe-Mazur and Bal, 1995; Reddy et al., 1996; Collins et al., 1998; Penner et al., 1998). 
In these studies it is not yet clear if the foetotoxic effects are as a consequence of maternal 
toxicity, or if FB 1 acts on the female or on the placenta, or if the absorbed FB1 crosses the 
placental barrier, potentially acting directly on the foetus (Penner et al., 1998). As 
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fumonisins have been found in maize products destined for human consumption 
(Doko and Visconti, 1994; Trucksess et al., 1995), there may be considerable human 
exposure via ingestion of contaminated food during pregnancy (Ferguson et al., 1997). 
2.5 MECHANISM OF ACTION OF FUMONISINS 
The biochemical mode of action of the fumonisins has not been fully elucidated, but they 
have been shown to completely block de nova sphingolipid biosynthesis in rat hepatocytes 
in culture at concentrations (1 µM) that could plausibly be achieved in vivo 
(Wang et al., 1991c). Similar disruption of sphingolipid metabolism has been noted in 
cultured porcine renal cells (Yoo et al., 1992) and in cultured cerebellar neurons 
(Merrill et al., 1993a). 
Fumonisins are structurally similar to sphingosine (So) and sphinganine (Sa) (Fig. 2.6), the 
long-chain (sphingoid) base backbones of more complex sphingolipids. The specific site 
of FB 1 action appears to be the enzymes sphinganine and sphingosine-N-acyltransferases 
(ceramide synthases) (Fig. 2.7). The similarity of the polyhydric alcohol moiety of FB1 to 
So and Sa allows FB 1 to be recognised as substrate (transition state or product analogs) for 
the enzyme N-acyltransferase (Merrill et al., 1996). 
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apparatus, while degeneration of complex sphingolipids occurs in the lysosomes, 
endosomes and the plasma membrane, with degeneration of free sphingoid bases 
occurring in the cytosol (Riley et al., 1996). 
Fumonisin B1 alters cell morphology (Yoo et al., 1992), cell-cell interactions (Ramasamy 
et al., 1995), the behaviour of cell-surface proteins and protein kinases (Huang et al., 
1995), the metabolism of other lipids (Smith and Merrill, 1995) and cell growth and 
viability (Yoo et al., 1992; Schroeder et al., 1994; Gelderblom et al., 1995). These 
changes are not fully understood and may have multiple causes; however, as sphingolipids 
are associated with each of these processes, most ( or all) of the cellular effects of 
fumonisins are likely to be consequences of interference with sphingolipid metabolism 
(Merrill et al., 1996). 
Studies on various animal species exposed to fumonisins have indicated that a similar 
disruption of sphingolipid biosynthesis occurs in vivo. Elevated levels of sphingoid bases 
were noted in the sera of ponies fed FB 1 -contaminated feed (Wang et al., 1992c). Specific 
alterations were observed in the Sa: So ratio. Similarly, in pigs that consumed total 
fumonisins up to 175ppm in the diet, serum Sa and especially the Sa:So ratio were 
sensitive markers for fumonisin exposure (Riley et al., 1993 ). Elevation of Sa and the 
Sa:So ratio have also been noted in the serum of chickens (Weibking et al., 1993), rabbits 
(Gumprecht et al., 1994), rats (Riley et al., 1994; Voss et al., 1998) and non-human 
primates (Shephard et al., 1996a). 
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2.6 CONFLICTING EVIDENCE ON THE ROLE OF THE DIET IN 
PRE-ECLAMPSIA 
Much of the evidence that has been produced to support the view that the incidence of 
pre-eclampsia can be influenced by the diet comes from the effects seen in wartime. 
Unfortunately this evidence is suspect, as no account was taken of the changing patterns of 
reproduction during wartime, with a fall in the birthrate and a change in the parity. Other 
factors, possibly even mental strain, might have influenced the incidence of pre-eclampsia 
in these circumstances (MacGillivray, 1983). 
In the United States, Brewer (1966) noticed a higher incidence of pre-eclampsia in 
underprivileged classes, particularly blacks, and assumed this was due to the poorer diet of 
these classes. There is a high incidence of pre-eclampsia in India and a poor level of 
nutrition (MacGillivray, 1983). There is however, a lack of established evidence to relate 
poor nutrition and the incidence of pre-eclampsia among women of a lower social class. A 
survey by Van Eeden and Gericke (1996) showed that a change in the socio-economic 
status of South African women did bring about changes in dietary patterns, habitual food 
intake and frequency of traditional food intake. However, maize and maize-based foods 
continued to be a staple component of their diet. 
A study conducted by Wacker et al. (1998) described a relationship between climate and 
the occurrence of pre-eclampsia in three districts of Zimbabwe. It was hypothesised that 
humidity and temperature impacted on vessels or the production of vasoactive substances. 
The peak in the incidence of pre-eclampsia occurred at the start of the rainy season with a 
lower incidence occurring in months with a very low or even no rainfall. Dry and rainy 
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seasons influence the agricultural yields and therefore nutritional status could play a role 
in the pathophysiology of pre-eclampsia (Wacker et al., 1998). The nutrition of the patient 
may not cause pre-eclampsia, but it may modify the course of the disease. 
2.7 CONCLUSION 
This review has highlighted that a great deal of research has been undertaken in an effort 
to elucidate the pathophysiology of pre-eclampsia. It has also highlighted the multifaceted 
nature of this disease. In vitro and in vivo studies on the impact of fumonisins on animal 
health have been extensive, on human health, less so. The results from animal studies 
cannot easily be extrapolated to the human situation due to the interspecies differences 
between the structure and cell compositions of the various animal systems, and the 
consequent varying cytotoxic effects of fumonisins. The significant contribution of maize 
to the diet of the black population of South Africa, and therefore the potential diet-toxicity 
interaction, warranted the present pilot study to ascertain whether FBI may be associated 




Patients' age, parity, period of gestation, obstetric and neonatal outcomes were recorded. 
In each case, history, clinical findings on physical examination, results of haematological 
and biochemical tests, and special investigations were also documented. 
3.1 PRE-ECLAMPTIC PATIENTS 
Twenty African female in-patients presenting with hypertension (BP 2'. 140/90mmHg), 
proteinuria (dipstick � 2+ proteinuria on more than three occasions) and /or oedema 
between 24 and 34 weeks of gestation were included in this study. Patients presenting with 
aproteinuric hypertension, those with multiple pregnancies (i.e., twins, triplets, elc.) and 
those with a previous history of chronic hypertension, were excluded from the study. 
Parity was not used as an exclusion criterion. 
The age of the 20 pre-eclamptic patients ranged from 15 to 40 years 
(mean: 27 ± 8.4 years) (Table 3.1). On admission, the mean systolic blood pressure was 
165. 5 ± 23 .3mmHg (range: 140 220mmHg) and the mean diastolic blood pressure was
109 ± 11.2 mmHg (range: 100 130mm Hg) (Table 3.1). The gestational age of these 
patients was between 24 and 41 weeks (mean: 33.6 ± 4.1 weeks) (Table 3.2). Nine patients 
(45%) were primiparous and 11 (55%) were multiparous (Table 3.2). 
Table 3.1: Demographics of the pre-eclamptic patients. 
PATIENT AGE BLOOD PRESSURE 1PROTEINURIA 
(YR) (mmHg) Dipstick(AMES) 
1 18 160/100 
2 33 190/130 
3 19 200/110 
4 33 180/110 
5 15 210/130 
6 15 150/100 
7 37 160/120 
8 24 160/120 
9 31 150/100 
10 25 140/100 
11 38 160/100 
12 37 150/110 
13 36 220/130 
14 17 140/100 
15 40 150/100 
16 20 150/110 
17 29 160/100 
18 25 180/110 
19 18 150/100 
20 28 150/100 
Mean ± 
3
SD 27 ± 8.4 
4SBP 166 ± 23.3 
5DBP 109 ± 11.2 
I Degree of seventy of protemuna (D1pst1ck Test). 2+, 3+ 
2Oedema: present +
3SD: standard deviation 
4SBP: systolic blood pressure 











































Table 3.2: Parity and gestational age of the pre-eclamptic 
patients. 
PATIENT 1PARITY GESTATIONAL AGE 
(weeks) 
1 G1Po 28 
2 G3P2 36 
3 G1Po 34 
4 G3P2 39 
5 G1Po 36 
6 G1Po 24 
7 G6P3+2 32 
8 G2P1 30 
9 GJ>3 37 
10 G1Po 33 
11 GJ>3 41 
12 G3P2 32 
13 G2P1 31 
14 G1Po 32 
15 G6P5 34 
16 G1Po 36 
17 GJ>o+j 29 
18 G3P2 33 
19 G1Po 38 
20 G1Po 37 
Mean± "SD G: 2.45 ± 1.7 33.6±4.1 
P: 1.2± 1.4 
G - grav1da md1cates the total number of pregnancies 
P - parity indicates the number of pregnancies that have resulted in the birth 
of viable offspring 
2SD: standard deviation 
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3.2 CONTROL PATIENTS 
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Twenty African female in-patients with no signs of hypertension or proteinuria throughout 
their pregnancies, or chronic hypertension, were included in this study. These 
normotensive patients were matched, as closely as possible, to the pre-eclamptic patients 
by age, period of gestation and parity. It was not always possible to match the two groups 
by period of gestation as the pre-eclamptic patients often delivered earlier than the 
normotensive patients in order to alleviate the symptoms of pre-eclampsia. 
The mean age of the control patients was 27 years, with a range of 16 43 years 
(Table 3.3). The mean systolic blood pressure was I 16.8 ± I0.3mmHg 
(range: 100 130mmHg) and the mean diastolic blood pressure was 74.5 ± 7.6mmHg 
(range: 60 - 90mmHg) (Table 3.3). The gestational age ranged from 28 to 40 weeks 
(mean: 36.4 ± 4.2 weeks) (Table 3.4). Ten patients (50%) were primiparous and IO (50%) 
were multiparous (Table 3.4). 























Mean ± 1 SD 27 ± 8.5 
. .
SD. standard dev1at1on 
2SBP: systolic blood pressure 























:tSBP 117 ± 10.3 
3DBP 74.5 ± 7.6 
38 
Table 3.4: Parity and gestational age of the control patients. 
PATIENT 
1
PARITY GESTATIONAL AGE 
(weeks) 
1 G1Po 28 
2 GJ>s 37 
3 G1Po 28 
4 G3P2 40 
5 G1Po 37 
6 G1Po 29 
7 G3Pt1 38 
8 G1Po 38 
9 G2P1 38 
10 G1Po 39 
11 G3P2 38 
12 GJ>s 40 
13 G2P1 37 
14 G1Po 37 
15 G6Ps 40 
16 G1Po 38 
17 G1Po 29 
18 G2P1 40 
19 G3Pt 1 40 
20 G1Po 36 
Mean± :zSD G: 2.3 ± 1.78 36.4 ± 4.2 
P: 1.2 ± 1.77 
G - grav1da md1cates the total number of pregnancies 
P - parity indicates the number of pregnancies that have resulted in the birth 





The predicted outcome of the pre-eclamptic group would be 20 babies. Of these, 16 were 
born alive, reflecting a foetal mortality rate of 20% in the group of patients studied. The 
foetal mortality rate was 10% in primiparous (two stillbirths) and I 0% in multiparous 
patients (two stillbirths). Table 3.5 outlines the mode of delivery, birth weight and sex of 
the neonates born to pre-eclamptic mothers. All twenty births in the control group were 
live births (Table 3.6). The mean birth weight of the pre-eclamptic group was significantly 
lower than those of the control group (mean: 2.3kg ± 0.85 vs 3.0kg ± 0.65; p<0.05). 
3.2 MATERNAL COMPLICATIONS 
Two patients within the pre-eclamptic group developed eclampsia, one patient developed 
septicaemia post caesarean section, and one patient suffered f om abruptio placentae 
(Table 3.5). There was no record of any maternal complications in the control group. 
Table 3.5: Neonatal outcome, delivery and maternal complications of 
pre-eclamptic patients. 
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Patient Weight of 1 Sex of iDelivery JPerinatal "Complications 
baby (kg) baby mortality 
1 1.4 M C/S Alive 
2 2.6 F C/S Alive 
3 2.3 M C/S FSB 
4 4.4 M C/S Alive 
5 2.7 M C/S Alive 
6 1.0 F NVD FSB 
7 1.1 F C/S Alive 
8 1.9 F CIS Alive 
9 2.4 F NVD Alive 
10 2.0 F C/S Alive 
11 3.3 M C/S Alive 
12 1.9 M CIS Alive 
13 NR NR C/S FSB 
14 1.5 M C/S Alive 
15 3.1 M NVD Alive 
16 3.7 M NVD Alive 
17 0.95 F C/S FSB 
18 3.1 F NVD Alive 
19 3.2 M NVD Alive 
20 2.7 M C/S Alive 
Mean± SD 2.3 ± 0.85 
I 
Sex of baby: M - male, F - female 
2
Delivery: C/S - caesarean section, NVD - normal vaginal delivery 
3Perinatal mortality: FSB - fresh stillbirth 
4









Table 3.6: Neonatal outcome and delivery of control patients. 






















Mean± SD 3.0 ± 0.65 
I Weight of baby. NR - not recorded 
2Sex of baby: M - male 
F - female 
NR - not recorded 
3Delivery: C/S - caesarean section 
NVD - normal vaginal delivery 












































Ethical approval for this study was obtained from the Ethics Committee, Faculty of 
Medicine, University of Natal. Placental and blood samples were obtained from 
pre-eclamptic and normotensive (control) patients admitted to the Labour Ward at KEH, 
Durban, South Africa. Patients were given a complete explanation of the study and were 
asked to sign a consent form (Appendix 3.1) if they agreed to take part in the study. 
Patients were assured that any information that they provided would remain confidential. 
Patients were also assured that the samples that they provided would be used for the 
purpose of the study only. 
CHAPTER4 
AN IMMUNOHISTOLOGICAL ANALYSIS OF PLACENTAL 
TISSUE FOR THE PRESENCE OF FUMONISIN B1 •
4.1 INTRODUCTION 
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Microscopy is an indispensable tool in the study of cellular structure and function. The use 
of light and electron microscopy has led to the intensification of ultrastructural 
investigations of organs and tissues, resulting in the accumulation of important 
information about their fine structure. Pathological processes, previously studied by 
classic morphological methods, have acquired new interpretation based on information of 
intracellular organisation and reconstruction. The incorporation of immunological 
techniques into microscopy has intensifed research on cell components, and has led to the 
increased use of antibodies as laboratory reagents. To confirm the presence of antigens in 
altered cellular organelles, many researchers have used antibodies for their detection. The 
increasing commercial availability of various antibodies has expanded our knowledge of 
internal structure and classification of cells (Goers, 1993). 
Immunohistochemistry (IHC) was used in this study to facilitate the detection of labelled 
antigens at the light microscope level, by means of specific antigen-antibody reactions 
tagged by the visible label 3,3 diaminobenzidine tetrahydrochloride (DAB). The Avidin­
Biotin (AB) method of detection (Appendix 4.1) was applied to immunolocalise fumonisin 
within the placental tissue. 
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The direct method of immunochemical analysis involves the application of a labelled 
primary antibody to the tissue section to identify antigenic sites. In this investigation 
however, only the indirect method was used due to its increased sensitivity. In the AB 
method used, the primary antibody was unlabelled and was identified by a labelled 
secondary antibody raised to the Immunoglobulin G (IgG) of the species providing the 
primary antibody. As at least two secondary antibody molecules can bind to each primary 
antibody, this method was more sensitive than the direct method, i.e., smaller amounts of 
antigen were detected, or a stronger signal was given for the same number of bound 
primary antibody molecules. An additional advantage was that a labelled secondary 
antibody to the IgG of one species could be used to identify any number of primary 
antibodies raised in that species (Polak and van Noorden, 1986). 
The term "image analysis" is reserved for a special discipline in pathology that aims to 
obtain diagnostically important information in an objective and reproducible manner, by 
measuring and counting (Meijer et al., 1997). Image analysis is currently applied in 
routine diagnostic cytopathology and histopathology as well as in research. Although there 
are three different areas of image analysis, they are not mutually exclusive. These areas 
are measuring morphological characteristics of tissues, cells, nuclei or even nucleoli; 
counting of cell or tissue components; and cytometry and pattern recognition, which aims 
to measure cytochemical, histochemical, and molecular cell or tissue features such as the 
deoxyribonucleic acid (DNA) content of nuclei, and to classify cells according to the 
distribution pattern of these features in cells or nuclei (Meij er et al., 1997). 
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In this study the use of image analysis allowed for the assessment of the proportion of 
cells that were positive for the immunohistochemical stain DAB as well as the distribution 
of staining intensities over the cells. 
4.2 MATERIALS 
All reagents, solvents and chemicals were purchased from MERCK (South Africa) unless 
otherwise stated. Light microscopy materials (e.g., paraffin wax, specimen holders and 
glass slides) were purchased from Capital Enterprises. Poly-L-Lysine was purchased from 
Sigma Chemical Company (S.A.) and bovine serum albumin (BSA) was purchased from 
Roche Diagnostics. A Pap delimiting pen and DAB chromogen tablets were purchased 
from DAKO Corporation (Southern Cross Biotechnology). The polyclonal primary 
antibody (sheep anti-FB1) was purchased from Neogen, USA and the secondary antibody 
(rabbit anti-sheep IgG) was purchased from Sigma Chemical Company (S.A.). 
4.3 METHODS 
4.3.1 Collection of specimens 
Once the placenta was delivered, blocks of tissue (5cm
3
) were cut from the periphery and 
the centre of the placenta. These tissue blocks were immediately dipped in physiological 
saline (0.9%) to remove excess blood and then immersed in 10% formalin to avoid 
autolysis and bacterial degradation. All specimens were transported to the laboratory in 
this manner. 
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4.3.2 Specimen preparation 
The placental tissue was fixed in 10% formalin for 12 hours at 24 °c before being 
processed in a Shandon automatic processor. The automated schedule outlining the 
fixation, dehydration, clearing, infiltration and embedding (Table 4 .1) was carried out by 
the Department of Anatomical Pathology, University of Natal. Wax embedded tissue 
sections (3-5µm) were cut on a Leica RM2025 rotary microtome, heat fixed onto glass 
slides and stained routinely with haematoxylin and eosin (H&E) (Humason, 1972). 
Glass slides were coated with poly-L-Lysine according to the manufacturer's instructions. 
Poly-L-Lysine is an adhesive subbing solution for immunoperoxidase and routine 
histological staining preparations. The polycationic nature of the molecule allows 
interaction with the anionic sites of tissue sections resulting in strong adhesive properties 
(Huang et al., 1983). 
Wax embedded tissue sections (3-5µm) picked up on poly-L-Lysine coated slides were 
analysed for the presence of FB 1 using IHC. The procedure employed for IHC is outlined 
in Table 4.2. All antibodies and streptavidin-HRP were diluted to a pre-determined 
appropriate dilution factor, using a 1 % BSA (w/v) (Appendix 4.2) in Tris Buffered Saline 
(TBS) (0.05M, pH7.2) solution as the diluent (Appendix 4.2). The use of method controls 
involved the omission of the primary antibody and its replacement with TBS on the tissue 
specimens. Kidney tissue from FB 1 -treated rats was used as a positive control while 
kidney tissue from untreated rats was used as a negative control. The rat tissue blocks 
were obtained from the Medical Research Council (MRC), Tygerberg Hospital, South 
Africa. The animal care and use protocol was approved by the Ethics Committee affiliated 
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with the MRC for research undertaken by the Programme on Mycotoxins and 
Experimental Carcinogenesis. 
Table 4.1: Fixation, dehydration and embedding schedule for routine light 
microscopy. 




Fixation 10% Formalin 24 12hrs 
Dehydration 70% Ethanol 24 1hr 
Dehydration 90% Ethanol 24 1hr 
Dehydration 100% Ethanol 24 1hr 
Dehydration 100% Ethanol 24 1hr 
Clearing Xylene 24 1hr 
Clearing Xylene 24 1hr 
Vacuum filtration 1 Paraffin wax 60 1 hr 
Vacuum filtration 2 Paraffin wax 60 1 hr 
Embedding Paraffin wax 20 20 mins 
The H&E sections were viewed and photographed on a Zeiss photomicroscope using a 
Nikon FX camera. The tissue sections used for IHC were viewed on a Nikon Optiphot 
photomicroscope and the images were captured on a Sony 3CCD (charge coupled device) 
colour video camera. Image analysis of the captured images was performed using the 
Konitron Elektronik Imaging System 300 software programme at the Optics and Imaging 
Centre, University of Natal. 
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Table 4.2: Processing schedule for immunohistochemistry using the ABC method 
(modified after Polak and van Moorden, 1983). 
Procedure Temperature (°C)* Time 
Dewaxed in 100% xylene RT 10 mins 
Dewaxed in I 00% xylene RT 10 mins 
Dehydrated in I 00% ethanol RT 5 mins 
Dehydrated in 100% ethanol RT 5 mins 
Dehydrated in 100% methanol RT 20 mins 
Dehydrated in 90% ethanol RT 2 mins 
Dehydrated in 90% ethanol RT 2 mins 
Dehydrated in 70% ethanol RT 3 mins 
Washed in distilled water RT 5 mins 
Delimited specimen with a Pap pen to form a well 
for reagents 
Placed in a droplet of distilled water (200µ1) RT 1 min 
Incubated in 0.5% hydrogen peroxide (H2O2) in RT 30 mins 
methanol (200µ1/ 
Poured off H2O2-methanol 
Drop-washed in TBS (0.05M, pH7.2) (20ml) RT 
Incubated in 2% BSA (blocking agent) (20µ1/ RT 15 mins 
Blotted off excess BSA with fibre-free paper 
Placed in primary antibody (polyclonal sheep anti- 4 Overnight 
FB1) (1: I 00) (20µ1/ (12-14hrs) 
Drop-washed in TBS (0.05M, pH7.2) (20ml) RT 
Drop-washed in TBS:Tween 20 (0.1%) RT 30 sec 
Incubated in 2% BSA (blocking agent) (20ul/ RT 15 mins 
Blotted of excess BSA with fibre-free paper 
Placed in secondary antibody (rabbit anti-sheep IgG 
conjugated to biotin) ( 1: I 00) (20µ1/ 
RT 30 mins 
Drop-washed in TBS (0.05M, pH7.2) (20ml) RT 
Placed in biotinylated streptavidin-HRP (1: 150) ' RT 30 mins 
(20µ1/ 
Drop-washed in TBS (0.05M, pH7.2) (20ml) RT 
Blotted off excess TBS with fibre-free paper 
Stained with DAB (made up according to the RT 5-10 mins
manufacturer's instructions) (in the dark) with
Do not overstain checking
Drop-wash with distilled water (20ml) RT 5 mins 
Stained with haematoxylin RT 3-5 mins 
Blued with hot water 60 5 mins 
Coverslipped using glycerol jelly RT 
ffDuring all incubation periods, specimens were placed in a moist chamber to prevent 
them from drying out. 
•RT - Room Temperature
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4.3.3 Evaluation of immunohistochemistry 
In order to analyse the images they first had to be digitised. During the scanning of the 
image the intensity distribution of the selected area was digitised in two ways. The first 
was a quantification in the X- and Y-axis in the image surface through the frame 
measurements, the second was a quantification of the intensity values through the 
technology of the frame grabber which digitises the analog signal. The result was a 
rectangular matrix of screen pixels. The image area was determined by the video camera 
and consisted of a maximum of 784 columns and 600 lines. The pixels in this system were 
represented as numbers ranging from Oto 255. The grey values represented the intensity of 
the reaction between the antigen-antibody complex and the DAB chromagen over the 
entire area of possible X- and Y-coordinates (Konitron, 1995). 
Binary images are a special kind of grey scale image. They contain two grey values, 
normally zero and one or zero and 255 (Russ, 1992). A grey value of zero was black and a 
grey value of 255 was white. The grey values in between were displayed in grey 
increments. Binary images were used as a mask to modify the grey scale image. This was 
done to blank out non-specific staining and to create a display in which the regions of 
interest could be measured. Fig 4.2 shows an example of a mask overlay. Binary images 
were a necessary transition step from the original to the quantitative data. They defined the 
areas which were to be analysed. 
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The functions to carry out the processing steps were part of a macro file which was 
developed only once and stored. Fig. 4.3 shows the macro that was specifically designed 
for the analyses of the placental tissue sections used in this study. The mean grey values 
obtained for each tissue section were statistically analysed using the Student t-test. 
Macro C:\KS300\CONF\MACROS\NIKKI.MCR 
0 Imgdelete 1 
1 Gclear 0 
2 Tvlive 
3 Tvinput 1 
4 Imgdelete 2 
5 lmgload "d:\267dinter.tir', 1 
6 ImgRGB2grey 1,2 
7 Scalint 2, 3, 42, 210, 0, 225 
8 Dislev 3, 4, 20, 157, 1 
9 Binscrap 4, 5, 0, 1000, 0 
10 MSsetgeom 
11 Mssetframe 
12 Mssetfeat "FIELDFEAT" 
13 Mssetfeat "DRA WFEAT" 
14 Msmeasmask 5, 1, "database", O, 2, 10 
15 Msdrawmask 5,1 
16 lmgdisplay 1 
17 Gmerge 1, 255 
18 lmgsave 1, "d:\nikovd.tif 
Figure 4.3: Unique macro designed for the image analysis of placental tissue sections 
using Kontron Elektronik Image system KS300 software. 
4.4 RESULTS AND DISCUSSION 
Each tissue section was divided into stem, intermediate and terminal villi, allowing for the 
assessment of the staining pattern and the quantitative analysis of the intensity of the 
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reaction among the three basic villi and between the two groups (i.e., pre-eclamptic and 
control). 
4.4.1 Haematoxylin and eosin staining 
Syncytial knots were present in both the pre-eclamptic (Fig. 4.4) and the normal placentae 
(Fig. 4.5). Syncytial knots refer to the aggregation of syncytial nuclei to form 
multinucleated protrusions from the villous surface. The presence of these knots has been 
taken as an index of placental maturity and it has been stated that in the normal placenta 
approximately 30% of villi show such knots (Benirschke, 1962, Merrill, 1963, Benirschke 
and Kaufmann, 1990). Figures in excess of this would imply excessive placental ageing 
however, increased numbers of syncytial knots have been observed in placentae taken 
from women suffering from diabetes mellitus and from pre-eclampsia (Benirschke and 
Kaufmann, 1990). There was no difference in the number of syncytial knots in tissue taken 
from the periphery of the placenta and tissue taken from the centre of the placenta in both 
the control and the pre-eclamptic groups. In the pre-eclamptic group however, the 
syncytial knots were more numerous in the terminal villi than in either the intermediate or 
the stem villi. 
Syncytial knots may serve as the first steps of villous sprouting, i.e., the formation of new 
villi (Boyd and Hamilton, 1970; Cantle et al., 1987), as a mechanism of extrusion of old 
syncytial nuclei (Jones and Fox, 1977), or as simple mechanical aids to establish junctions 
between neighbouring villi (Cantle et al., 1987). Hypoxia is believed to be responsible for 
the placental changes in women with pre-eclampsia (Fox, 1978). This sprouting is 
considered to be an adaptive change to altered maternal blood flow or oxygen content of 
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intervillous blood (Benirschke and Kaufmann, 1990). The capillary response to long-term 
hypoxia is characterised by capillary branching and therefore an expanded capillary bed, 
in an attempt to compensate for the decreased capillary diameter. 
The deposition of a fibrinous substance in the stroma was seen in all villous types in the 
normal and pre-eclamptic placentae (Fig. 4.4). Fox (1978) noted that the peripheral 
regions of the placenta showed an increase in the number of villi with excessive stromal 
fibrosis compared to the villi of the central regions. This difference was not noted in this 
study. Regarding its functional importance, many researchers suggest that it is no longer 
justifiable to classify fibrin deposition merely as being the result of degenerative processes 
caused by placental ageing or altered blood flow and nutrition, but as an unavoidable 
constituent of the normal placenta (Benirschke and Kaufmann, 1990). 
In the normal placentae the cytotrophoblastic cells were few in number and not very 
prominent as they tended to be flattened between the syncytiotrophoblast and the 
basement membrane (Fig. 4.5). The basement membrane separates the trophoblast from 
the villous stroma The cytotrophoblastic cells retain their capacity to multiply and 
represent an inactive germinative layer which can be stimulated to replace damaged or 
destroyed syncytiotrophoblast (Fox, 1978). In contrast there were numerous 
cytotrophoblastic cells in the pre-eclamptic placentae (Figs. 4.6a and 4.6b ). This is 
regarded as the most striking and characteristic feature of villi in pre-eclampsia (Fox, 
1978; Soma et al., 1982, Benirschke and Kaufmann, 1990). A study by Genbacev et al., 
(1996) demonstrated that oxygen tension is one factor that regulates human 
cytotrophoblast differentiation along the invasive pathway. In a hypoxic environment, the 
cells carry out only the initial stages of their normal differentiation programme. 
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Comparing the invasiveness of cytotrophoblasts cultured in 2% and 20% oxygen, these 
investigators demonstrated that cytotrophoblasts in a low oxygen tension environment had 
greatly reduced invasiveness. Hypoxia therefore changes the balance between proliferation 
and differentiation in cytotrophoblasts (Genbacev et al., 1996). 
Villous capillaries were prominent and the lining endothelial cells had a fattened 
elongated appearance. These capillaries were sinusoidal and dilated. The syncytium in 
many villi was thin and anuclear where the capillaries were large, and appeared to fuse 
with the capillary wall, reducing the area between the capillary and the intervillous space. 
This "fused" area is referred to as a vasculo-syncytial membrane (Fig. 4. 7). Several of the 
pre-eclamptic villi were hypovascular, with small, non-dilated and relatively 
inconspicuous vessels. These villi had fewer vasculo-syncytial membranes than normal 
villi of the same gestational age. The vasculo-syncytial areas represent the sites of closest 
approximation of maternal and foetal circulations and may therefore play an important 
role in foetal-maternal transfer of gases and metabolites. The reduced number of such 
membranes in the pre-eclamptic villi may have adverse effects on the foetus, such as 




4.4.2 Immunohistochemistry and image analysis 
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With peroxidase-labelled antibody techniques, the presence in the tissue of enzymatically 
active peroxidase, catalase and haemprotein, all capable of reacting with H2O2 and 
reducing DAB, has the ability to confuse the final location of the antigen. This was a 
problem in paraffin sections although much of the native enzyme activity was destroyed 
during the processing. Blocking the endogenous "peroxidase" with H202 at the start of the 
procedure was suggested (Heyderman, 1979) and was found to be effective. This ensured 
that non-specific binding of the DAB chromagen to tissue constituents did not constitute a 
false-positive reading. 
Immunohistochemical analysis of the 20 pre-eclamptic specimens revealed the presence of 
FB1 in all of the specimens screened. A positive-FB 1 reaction was also seen in the control 
specimens screened. This was not unexpected as FB1 could be present in the diet of both 
the pre-eclamptic and the control groups. The method control (Fig.4.8) lacked non-specific 
binding of the secondary antibody or the DAB chromagen to tissue constituents. The 
method specificity was confirmed using FB1-treated (Fig. 4.9) and untreated (Fig. 4.10) 








The quantitative results from the image analysis of these tissue sections are presented in 
figures 4.19- 4.24. The intensity of the stain (mean grey values) in the control stem villi 
ranged from 84.99 to 101.2 (mean: 93.9 ± 7.2), in the intermediate villi the range was 
113.89 to 85.78 (mean: 96.5 ± 7.1), and in the terminal villi the range was 86.77 to 101.4 
(mean: 94.7 ± 7.2). In the pre-eclamptic stem villi the mean grey value representing the 
staining intensity of FB 1 positivity was 106.9 ± 17.9 (range: 115.29 -162.16), in the 
intermediate villi 100.6 ± 13.2 (107.79 152.68) and in the terminal villi 109 ± 17.4 
(range: 99. 73 146.42). Within each group the same colour was used to represent the 
different villous types from the same patient. 
Within the pre-eclamptic group, 55% of the specimens analysed showed a higher FB 1
positivity in the stem villi than in the intermediate and terminal villi. One out of the 20 
specimens (5%) showed a higher staining intensity in both the intermediate and the 
terminal villi compared to the stem villous of the same specimen. The remaining 
specimens (40%) had a similar positivity for FB 1 in the stem, intermediate and terminal 
villi. 
The values of the pre-eclamptic group were all higher than those of the control group 
except for one sample in which the higher positive stain was found in the intermediate 
villous of a control sample. Within the control group, 85% of the stem villous samples 
analysed had a lower intensity of stain than either the terminal or the intermediate villi 
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Figure 4.23: Quantitative analysis of the immunolocalisation of FB1 in the 
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Figure 4.24: Quantitative analysis of the immunolocalisation of FB1 in the 
terminal villi of normotensive placentae. 
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There was a significant difference in the intensity of staining between the pre-eclamptic 
group and the control group in all three villous types (stem villi, p $ 0.0001; intermediate 
villi, p $ 0.05; terminal villi, p $ 0.0001). A previous study showed that the polyclonal 
antibody (sheep anti-FB1) did not react with either Sa or So (Biden, in press). If FB 1 is an 
exacerbating factor in the pathophysiology of pre-eclampsia, it may confirm the theory of 
Smarason et al., (1996), that a cytotoxic factor present in both normal and pre-eclamptic 
placentae, is shed into the maternal circulation in abnormal amounts in pre-eclamptic 
women. 
Smarason et al. (1993) showed that the syncytiotrophoblast microvillous membranes of 
normal placentae contain a factor(s) that specifically inhibits endothelial cell proliferation 
and disrupts the continuity of established endothelial cell monolayers without causing 
actual cell death. Smarason et al. (1993) also demonstrated that the same 
syncytiotrophoblast microvillous membrane preparations do not disturb other adherent or 
non-adherent cell types. The same study revealed no difference in the activity of 
equivalent amounts of syncytiotrophoblast microvillous membranes prepared from normal 
or pre-eclamptic placentae. Smarason et al. (1993) concluded that if this factor is relevant 
to the maternal endothelial dysfunction of pre-eclampsia it is because it is shed into the 
maternal circulation in abnormal amounts. This is supported by work confirming the 
presence of increased amounts of syncytiotrophoblast in the uterine vein blood of women 
with pre-eclampsia compared with samples from normal pregnant women 
(Chua et al., 1991). These intact trophoblastic cells probably do not enter the peripheral 
circulation, but are trapped in the capillaries of the lungs (Attwood and Park, 1961 ). 
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Smarason et al. ( 1996) confirmed the presence of a blood-borne endothelial cell 
suppressive factor in pre-eclampsia. The presence of FB1 in the syncytiotrophoblast 
microvillous brush border of both pre-eclamptic and control placental villi is consistent 
with the theory proposed by Chua et al., (1991) and Smarason et al., (1996) 
i.e., microvillous fragments containing a cytotoxic factor, are shed into the maternal
circulation in abnormal amounts in pre-eclamptic women. 
The presence of FB 1 in the cytotrophoblastic cells of the pre-eclamptic villi suggests that it 
could play a role in the abnormal invasion of the spiral arteries of the uterus, a feature of 
pre-eclampsia. As has already been discussed, Zhou et al., (I 993) observed that adhesion 
molecule switching by invasive cytotrophoblasts is abnormal in pre-eclampsia and the 
balance between those molecules that permit invasion and those that restrain it, is tipped in 
favour of the latter. Abado-Becognee et al., (1998) demonstrated that FB1 could induce 
DNA base modifications. By interacting with DNA, FB 1 may interrupt the 
cytotrophoblasts' cell cycle and alter gene expression. As a result these cells do not 
differentiate and an imbalance between proliferation and differentiation occurs. 
4.5 CONCLUSION 
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The immunolocalisation of FB1 in cells involved in the pathophysiology of pre-eclampsia 
suggests that FB 1 could be a contributing factor in this syndrome. Fumonisin B 1 may 
directly affect normal cellular function by causing DNA base modifications and thereby 
altering a cell's gene expression and protein repertoire, or it may act indirectly by inducing 
lipid peroxidation and inhibiting sphingolipid metabolism, the products of which cause 
cellular dysfunction. Although Sa and So accumulate in the cells due to the interference of 
sphingolipid metabolism by FB 1 , Biden (in press) demonstrated that there is no cross­
reactivity between the polyclonal antibody (sheep anti-FB1) and the sphingoid bases. 
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CHAPTERS 
ANALYSIS OF SERA FROM PRE-ECLAMPTIC AND 
NORMOTENSIVE PREGNANCIES USING HIGH-PERFORMANCE 
LIQUID CHROMATOGRAPHY 
5.1 INTRODUCTION 
Chromatography is the general name given to the methods by which two or more 
compounds in a mixture are physically separated by distributing themselves between two 
phases: a stationary phase, which can be a solid or a liquid supported on a solid; and a 
mobile phase, either a gas or a liquid, which flows continuously around the stationary 
phase. 
High-performance liquid chromatography (HPLC) is a widely used chromatographic 
technique for both qualitative and quantitative analysis of compounds. The mobile phase 
in HPLC is a liquid and the stationary phase is a solid with a very small particle size. 
Depending on the polarity of the stationary phase (polar, silica or non-polar, C 1 g-modifed 
silica) the HPLC can be differentiated into normal and reverse-phase, respectively. 
The fumonisin mycotoxins are polar molecules that are soluble in water and polar solvents 
and are thus ideally suited for determination by reverse-phase HPLC. Fumonisin B1 lacks 
an ultra violet (UV) chromophore (Fig. 5 .1) and is not inherently fluorescent. As a result 
sensitive detection of the low levels of toxin that are present in physiological samples, 




derivatising reagent 4-fuoro-7-nitrobenzofurazan gave a detection limit of l00ng/g, but 
also showed limited stability (Scott and Lawrence, 1992). It was similarly reported that 
l-dimethylaminonaphthalene-5-sulphonyl chloride ( dansyl chloride) formed a good
derivative but was not useful for maize due to analytical interferences (Scott and 
Lawrence, 1992). 9-Fluorenylmethyl chloroformate has been used as a sensitive reagent 
for fumonisin determination in rodent feed, forming derivatives which were stable for at 
least 72 hours and which had a detection limit of 200ng/g (Holcomb et al., 1993). Another 
derivatising reagent that has been used and which yields stable derivatives is 
6-aminoquinoyl N-hydroxysuccinimidylcarbamate. The report gives an apparent detection
limit of 260ng/g (Velazquez et al., 1995). In this study OPA was the derivatising reagent 
of choice due to its sensitivity, reproducibility and convenience of use. A reaction time of 
1 minute was permitted. 
Prior to HPLC analysis, the samples had to be extracted and purified to remove matrix 
impurities and to concentrate the FB 1 (Shephard, 1998). Extraction of these fumonisins 
and related compounds from food matrices was achieved using either acetonitrile-water 
(1: 1, v/v) or methanol-water mixtures containing 70-80% methanol (Bennett and Richard, 
1994). Aqueous acetonitrile (with 30-60 minutes shaking) was reported to give superior 
extraction efficiency compared to aqueous methanol (Rice et al., 1995). Other workers 
reported slightly better efficiencies for methanol-water (3: 1, v/v) using homogenisation for 
between one and five minutes (Sydenham et al., 1992b ). This step was achieved either by 
solid-phase extraction (SPE) on reverse-phase (C1s) or strong anion-exchange (SAX) 
cartridges, or by immunoaffinity columns. Strong anion-exchange cartridges achieved 
superior purification over reverse-phase cartridges, but required monitoring of the pH of 
the sample extract and careful control of elution fow-rates at not more than 1 ml/min for 
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reproducible recoveries (Sydenham et al., 1992b). Large variations in recovery from C18 
cartridges were noted due to interactions of the fumonisins with active sites on the sorbent 
(Bennett and Richard, 1994). In addition to reverse-phase and SAX cartridges, SPE 
sorbents containing both these functionalities yielded good recoveries of fumonisins over a 
wide pH range. As an alternative to SPE, immunoaffinity columns, containing antibodies 
reactive with fumonisins, provided a more selective purification of sample extracts and 
were commercially available (Shephard, 1998). These columns have been applied to the 
determination FB1 in maize (Sydenham et al., 1995), in milk (Scott et al., 1994) in beer 
(Scott and Lawrence, 1995) and in sweet corn (Trucksess et al., 1995). These columns 
have a limited capacity which should not be exceeded, otherwise the sample must be 
diluted and reanalysed. 
Fumonisins are an important contaminant of maize. As a result considerable effort has 
been spent in the assessment of the performance characteristics of the various methods 
used to detect FB 1 in maize and maize-based feeds and foodstuffs. However, there is very 
little literature on the efficiency of methods for the determination of fumonisins in 
physiological samples. Methods that are used are adapted from methods used in food and 
feed analysis, with detection limits above the low levels of FB 1 that are found in 
physiological samples. The physiological samples that have been analysed have been 
taken from laboratory animals fed FB 1 contaminated feed. Processing physiological 
samples for fumonisin determination has generally followed the same principles as for 
food matrices. Both animal plasma and urine samples were cleaned up on SAX SPE 
cartridges with minor modifications to the above methods, while animal faecal extracts 
were cleaned-up on C1 8 cartridges (Shephard et al., 1994b). Our research group is 
apparently the first to carry out determination of FB 1 in human physiological samples that 
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have been naturally contaminated with FB1. Recent research focused on the application of 
HPLC analysis of faeces (Chelule et al., 2000), sera (Reddy, 1999; Biden, 2000) and 
cerebro-spinal fluid (Palanee, 2000). 
The HPLC-analysis of serum allows investigators to determine whether or not FB 1 enters 
the general circulation via the consumption of FB 1 contaminated food. By analysing both 
serum from the umbilical cord and maternal serum from pregnant women exposed to FB 1 
in their diet, it is possible to determine whether FB 1 crosses the placenta, and therefore has 
the potential to act directly on the foetus. 
The aim of this study was to establish an HPLC method suitable for the detection of low 
levels of FB 1 in sera of pregnant women as well as their foetuses. Furthermore, it was of 
interest to correlate the levels of FB 1 in both of these fluids as well as to correlate 
incidence of pre-eclampsia with serum concentrations of FB 1 . 
5.2 MATERIALS 
All analytical-grade and HPLC-grade reagents, solvents and chemicals were purchased 
from MERCK (S.A.) unless otherwise stated. Water (HPLC-grade) was obtained by 
filtering water previously purified by a Millipore system through a 0.45µm filter. Solvent 
mixtures were degassed by sonication before use. Bond-Elut SAX solid-phase extraction 
cartridges ( I 0ml capacity containing 500mg sorbent) were purchased from SM:M 
Instruments (S.A.). The HPLC system consisted of a Spectra Physics P2000 binary pump, 
an AS3000 autosampler and a FL2000 fluorescence detector (all by ThermoSeparation 
Products, SM:M Instruments, S.A.). The analytical column was a Waters NovaPak C1s 
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cartridge (4µrn, 150mm X 3.9mm,Waters, Microsep, S.A.) preceded by an HIRPB-lOC 
guard column (Hichrorn Ltd, SMM Instruments). Fumonisin B 1 standard was purchased 
from Sigma Chemical Company (S.A.). 
5.3 METHODS 
5.3.1 Preparation of fumonisin B1 standard stock solution 
The FB1 standard was dissolved in acetonitrile-water (1: 1, v/v) to form a stock solution 
with a concentration of 1 mg/ml. This stock solution was then used to prepare FB 1 standard 
concentrations of 20, 40, 50, 60, 100, 150, 200 and 400ng/ml. A standard curve was 
plotted using these dilutions (Appendix 5.1 ). 
5.3.2 Sample collection 
Consent to draw blood was obtained from 12 of the pre-eclamptic patients and eight of the 
control patients from whom placental samples were taken. Maternal blood (5ml) as well as 
cord blood (5ml) was collected. Maternal blood was collected by medical staff of the 
Labour Ward, KEH, in blood collection tubes containing the coagulant SSI gel. The 
umbilical cord was double clamped and blood was collected by syringe and needle as soon 
as the placenta was delivered, as it coagulated rapidly upon delivery. The cord blood was 
then transferred to collection tubes (containing the SSI gel). The maternal and cord blood 
samples were immediately transferred to the laboratory and serum was obtained by 
centrifugation at 1200g for IO minutes at room temperature. The serum was stored in 
sealed 1. 5ml Eppendorf tubes at -70
°
C until HPLC-analysis. 
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5.3.3 Sample preparation 
The method of sample preparation was that used by Reddy ( 1999). A 500µ1 aliquot of 
serum was deproteinised by the addition of 2. 5ml of methanol. The protein precipitate was 
centrifuged at 1200g for 10 minutes at room temperature. The sample supernatant was 
removed and applied to a preconditioned SAX cartridge. The SAX cartridge was 
preconditioned with 5ml of methanol followed by 5ml of methanol-water (3: I, v/v). 
Immediately after all of the sample supernatant was applied, the sorbent was successively 
washed with 5ml of methanol-water (3: 1, v/v) and 5ml of methanol. The toxin was then 
eluted from the sorbent with 10ml of 5% acetic acid in methanol. Using a Varian Vac Elut 
system, the flow rate through the SAX cartridge for both the application and the elution 
was controlled at lml/min. At no stage was the cartridge allowed to run dry. The eluate 
was evaporated to dryness at 60
°
C under a gentle stream of nitrogen. The residue was 
redissolved in 100µ1 of acetonitrile-water (1: I, v/v) and allowed to stand for 5 minutes 
prior to derivatisation and HPLC analysis. 
5.3.4 Derivatisation procedure 
Fumonisin B 1 in the sample residues after SAX clean-up was quantified by reverse-phase 
HPLC of a preformed OP A derivative. The OPA reagent was prepared by dissolving 
20mg of OPA in 600µ1 of methanol followed by the addition of 5ml of 0.1 M di-sodium 
tetraborate (adjusted to pH10.5) (Appendix 5.2) and 50µ1 of 2-mercaptoethanol. This 
reagent was stored in the dark at room temperature. Derivatised samples were prepared by 
mixing a 40µ1 aliquot of the redissolved cleaned-up sample extract with 80µ1 of OPA 
reagent. Due to the instability of the OPA derivative of FB1, each aliquot of extracted 
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sample was treated with the OPA reagent individually one minute pnor to HPLC 
automatic injection. 
5.3.5 Recovery determination 
Aliquots (1ml) of maternal serum were randomly selected from five different patients 
(three pre-eclamptic and two normotensive). A half (500µ1 aliquot) of each sample was 
spiked with 40ng of FB 1. The spiking was achieved by individually pipetting 100µ1 of the 
appropriate stock solution (400ng/ml in acetonitrile-water, I: 1, v/v) into a sample aliquot. 
The spiked samples were vortexed and allowed to stand for 5 minutes to ensure dispersal 
of the FB 1 into the sample. To the remaining 500µ1 aliquot of each sample I 00µ1 of 
acetonitrile:water (I: 1, v/v) was added and these samples served as blanks and were used 
to monitor base levels of FB1. Both the unspiked and the spiked samples were extracted 
and derivatised using the same methods described in section 5.3.3 and 5.3.4, respectively. 
5.3.6 Chromatographic analysis 
Reverse-phase HPLC analysis of the serum samples were carried out under isocratic 
conditions (flow-rate: 1.0ml/min.) using methanol-buffer (29:71, v/v) as a mobile phase. 
The buffer was O. IM NaH2PO4 (Appendix 5.3), adjusted to pH3.3 with orthophosphoric 
acid. Injection of 50µ1 of derivatised sample was performed in duplicate in order to 
confirm reproducibility. All data collected was processed using PC I 000 software 
(Thermo Separation Products, SMM Instruments, S.A.). Peak area was used to quantify 
the concentration ofFB1 present according to the formula, 
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C=K•Ac + B 
Where K and B are the coefficients obtained from the calibration curve, and Ac is the peak 
area. The observed concentration was converted into a concentration of FB I in the original 
sample by correcting for dilution and for percentage of recoveries. 
5.4 RESULTS AND DISCUSSION 
The method for analysis of the serum samples was based on the methods by Reddy ( 1999) 
(sample preparation) and Shephard et al., (1992) (chromatography). The sample 
preparation method was adopted without any significant modifications while the 
chromatographic analysis had to be optimised before it could produce meaningful results. 
The original method by Shephard et al., (1992) employed OPA derivatisation offumonisin 
with fluorescence detection and was applied to plasma and urine of laboratory rats fed an 
artificially FB1-enriched diet. Shephard's method was adapted from methods used to 
analyse culture material and feed and foodstuffs (Shephard et al., 1990; Plattner et al., 
1990). 
As the matrix of human serum differs from that of rat plasma it was necessary to use a 
method that provided efficient clean up of the serum to reduce the amount of polar 
compounds that eluted. Reddy (1999) applied a method adapted from Shephard et al., 
(1992), which involved SPE extraction of deproteinised human sera using SAX columns, 
with satisfactory results. However, the existing chromatographic method possessed an 
intrinsic drawback of only being applicable for the determination of relatively high levels 
of FB1• In fact, using chromatographic conditions suggested by Shephard et al., (1992) 
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(with excitation and emission wavelengths being 335 and 440nm, respectively) allowed 
for the detection of the toxin when present in amounts not less than 0.1 µg. By changing 
the excitation wavelength to 230nm during this study, it became possible to improve the 
detection limit for FB 1 by over 100-fold bringing it down to the level of 1 ng (which 
corresponds to a serum concentration of 4ng/ml when 50µ1 is injected). However, 
changing the excitation wavelength brought an unforeseen problem: the increased 
sensitivity of the detector led to the marked increase in intensity of the peaks due to the 
polar constituents of serum samples which would elute before FB1, causing detector 
overload. In order to reduce this interference without compromising sensitivity for the 
FB1, the detection parameters were modified. For the frst 4.5 minutes the emission 
wavelength was changed to 600nm and then returned to 440nm for the remainder of the 
run. The excitation wavelength remained at 230nm. 
The large amount of polar impurities detected indicated that the clean-up procedure for the 
serum samples was not very efficient. However, no attempt to optimise the sample 
preparation procedure was made as this exceeded the scope of the present study. The large 
amount of impurities present in samples affected the analytical HPLC column due to 
excessive absorption on the stationary phase. It was therefore necessary to use a guard 
column to prevent system blockage and reduction of column efficiency. Reproducibility of 
the retention time ofFB1 was found to be dramatically affected even by small variations in 
the composition of the mobile phase (i.e., methanol-buffer ratio) or the pH of the buffer. 
Thus utmost care was taken to ensure constant chromatographic conditions on different 
days of analysis of the samples. The identity of the fumonisin peak in serum samples was 
established by comparison with a chromatogram of the FB1 standard and 4-5 runs of 
samples were normally bracketed by running a standard. Figure 5.3 represents a typical 
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chromatogram of a serum sample together with the FB 1 standard (100ng/ml). The peak 
eluting just before FB 1 at around 5.2 minutes, was an impurity in the OPA reagent, which 
increased with time. In order to eliminate the possibility of overlap between the two peaks 
and to reduce the variation in the quantification of the results, the OP A reagent had to be 
prepared daily. The peak eluting at approximately 6.3 minutes could have been due to 
unreacted OPA. Thukur and Smith (1996) have termed such peaks "mystery peaks". 
Figure 5.4 shows the chromatograms of a maternal serum sample together with the cord 
serum sample from the same pre-eclamptic pregnancy. 
Once the method for HPLC analysis was optimised, the reproducibility of the method was 
tested by injection of the 1 00ng/ml FB 1 standard over several days which showed very 
little (0.17%) variability. The detection limit was established as 1 ng based on a signal to 
noise ratio of 4: I. Reproducibi I ity between two injections of the same sample was found to 
be excellent. The mean recovery of the method was determined using five samples 
(Table 5. I) and was found to be 91 %. 
Table 5.1: Recovery determination of five random sera samples. 
Sample FB1 concentration FB1 concentration Recovery 
of spiked sample of unspiked sample (%) 
(ng/ml) (ng/ml) 
1 422 49.3 93 
2 373 o· 93 
3 428 39.4 97 
4 425 48.7 94 
5 319 o· 80 
. 





In the control samples FB 1 was detected in three maternal samples. Fumonisin B1 was not 
detected in the cord sera from those pregnancies. Fumonisin B 1 was not detected in the 
remaining five control serum samples (maternal and cord). 
Shephard et al. (1992) showed that the bulk of the FB1 dosed to rats either by i.p. injection 
or by gavage was eliminated in the faeces as unmetabolised FB1 within 24 hours and there 
was no major retention of the mycotoxin in tissues. A higher level of FB 1 was found in 
urine in the i.p. case indicating that this route leads to higher levels of FB1 in the general 
circulation. The FB 1 recovered in faeces was either absorbed into the circulation and 
excreted in the bile or directly absorbed into the gut after i.p. injection. When dosed by 
gavage, FB 1 was excreted almost entirley unmetabolised in faeces. The absence of 
significant amounts in the urine suggested that large amounts do not reach the general 
circulation either due to low absorption or due to rapid biliary elimination during the first 
pass through the liver following absorption in the gut (Shephard et al., 1992). The 
biochemical effect of FB 1 in sphingolipid metabolism has been demonstrated to occur at 
low concentrations in that 0.1 µM FB 1 inhibits sphingosine N-acyl-transferase activity in 
rat liver microsomes by 50% (Wang et al., 1991c). 
The presence of FB I in the maternal circulation of the pre-eclamptic patients suggests that 
it may be released into the circulation in abnormal amounts compared to the control 
patients. Fumonisin B 1 appears to be capable of crossing the placenta where it may have a 
direct toxic effect on the foetus. Several pregnancy-related physiological alterations favour 
increased absorption of xenobiotics in humans. Gastric emptying and transport through the 
small intestine are delayed, allowing more complete absorption. Increased tidal volume 
and reduced residual lung volume favour increased absorption of volatile and soluble 
90 
substances through the lung. Due to increased blood flow to the skin and mucous 
membranes xenobiotics applied to these sites are more likely to be rapidly absorbed. 
Increased cardiac output results in increased tissue concentrations of absorbed xenobiotics, 
especially in organs that are highly perfused, such as the placenta and uterus (Hytten, 
1984). 
Pregnancy alters several factors that influence the distribution of xenobiotics. These 
include an increase in total body water and body fat, and a decrease in plasma building 
proteins (Hytten, 1984). The generalised oedema characteristic of pregnancy is due to a 
70% elevation of the extracellular fluid filled space, which represents an increased area for 
the distribution of xenobiotics. The increase in body fat can act as a reservoir for fat­
soluble compounds, which, when released during late pregnancy, can result in increased 
xenobiotic exposure to both mother and foetus. Many xenobiotics are bound to plasma 
proteins, predominantly albumin. This binding is usually reversible, saturable, and 
relatively non-specific. Plasma albumin concentration declines in the first half of 
pregnancy due to the increased maternal plasma volume and an actual decrease in total 
plasma content. For highly bound xenobiotics, the hypoalbuminaemia of pregnancy results 
in a decrease in the bound and a corresponding increase in the free plasma fraction. As the 
maternal plasma albumin concentration falls during pregnancy, levels of albumin in foetal 
plasma gradually increase. Since the biological activity of a xenobiotic is usually related to 
concentration of the unbound molecule (i.e., the free fraction in the plasma), changes in 
the degree of maternal and foetal binding can influence toxicity (Mason and Wise, 1991 ). 
The placenta should be viewed as a lipid membrane that permits bidirectional transfer of 
substances between maternal and foetal compartments rather than as a "barrier". The 
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FB1-fed rats accumulated toxic levels of sphingoid bases that are released from other 
tissues into the blood. It is possible that humans do not respond to FB 1 in the same way as 
the animal models that have been investigated. However, increased proteinuria and kidney 
damage and dysfunction are features of pre-eclampsia. In patients with the disease FB 1 
may be passed back into the general circulation due to decreased glomerular fltration. 
CHAPTER6 
CONCLUSION 
6.1 POSSIBLE ROLE OF FUMONISIN B1 IN PRE-ECLAMPSIA 
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Endothelial cell damage and oxidative stress, due to an increase in lipid peroxidation, is 
accepted by most investigators as major contributors to the pathophysiology of 
pre-eclampsia. Several processes play a role in the molecular events leading to cell 
damage: lipid peroxidation, covalent binding of xenobiotics or their metabolites to 
biomolecules, and inhibition of the synthesis of cellular macromolecules. Once lipid 
peroxidation is initiated, it can easily be propagated in the cellular environment where 
unsaturated lipids and oxygen are present. The oxidation of lipids is propagated by radical­
mediated chain reactions. Malondialdehyde (MDA) and a wide range of other oxidative 
products are formed as a consequence of this chemical process (Abado-Becognee et al., 
1998). Formation of MDA and other aldehydes has been regarded as significant as these 
compounds are toxic (Ennamany et al., 1995), mutagenic, genotoxic (Hadley and Draper, 
1990) and tumourigenic (Shen et al., 1994). 
Abado-Becognee et al. (1998) demonstrated that FB 1 induces lipid peroxidation in 
monkey kidney cells (Vero cells) to an extent that could alter the structure and function of 
the cellular membrane and block cellular metabolism. Lipid peroxidation is a very 
sensitive response of exposure to FB 1.
Lipid peroxidation affects plasma membrane integrity as well as other cellular organelles. 
Lipid peroxidation may also be related to the disturbance of cell signalling processes, 
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genotoxicity, mutagenicity and tumour promotion caused by FB 1, since it has been shown 
that the diene conjugates formed during lipid peroxidation can interact with DNA, yielding 
several types of adducts with nucleotide bases such as 1, N6-ethenoadenine and 3, N4-
ethenocytosine (El Ghissassi et al., 1995). The study by Abado-Becognee et al. (1998) 
demonstrated that low concentrations of FB 1 compatible with natural contamination levels 
in feed and foodstuffs, could induce oxidative damage, DNA base modifications and 
stimulate the carcinogenic process. 
Ramasamy et al. (1995) used cultured porcine pulmonary arteries to demonstrate that an 
elevation of the highly bioactive compound sphinganine, due to FB 1 altered sphingolipid 
biosynthesis, causes disruption of the endothelial barrier function. A disrupted or damaged 
endothelium will allow increased penetration of plasma components into underlying 
tissues. 
Platelets from patients suffering from pre-eclampsia are hyporesponsive to stimulation by 
agonists such as thrombin and ADP. Koner et al. (1998) demonstrated that alterations in 
membrane fluidity and activities of the signalling enzymes phospholipase C and protein 
kinase C, may contribute to the diminished platelet responsiveness observed in 
pre-eclampsia. Fumonisin B 1 causes repression of protein kinase C through the 
accumulation of sphingoid bases, potent inhibitors of this signalling enzyme (Merrill et al.,
1993b). 
6.2 AN ADDITIONAL ROUTE OF FUMONISIN B1 EXPOSURE 
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Isihlambezo is a herbal decoction used by many Zulu women in South Africa as a 
preventative health tonic during pregnancy. Though isihlambezo was found to be most 
popular among urbanites and clinic non-attenders, it was considered an important 
antenatal health care alternative by the majority of women surveyed (Varga and Veale, 
1997). 
A survey to determine the prevalence of herbal medicine use during pregnancy by women 
attending the antenatal clinic at KEH was undertaken by Mabina and Moodley (I 997). 
They reported a prevalence of 43. 7%. The study also suggested that if a patient had 
knowledge of the herbal medicine, there was a 50.3% chance that she used isihlambezo 
during pregnancy. The use of oral herbal medicine during pregnancy in women attending 
rural and urban clinics in Tanzania was 40.2% and 43.4%, respectively (Mbura el al., 
1985). A study in the upper Tugela area of Kwazulu/Natal reported a prevalence of the use 
of isihlambezo as 51.2% in hospital deliveries, and 75.4% in clinic deliveries (Morris and 
Mdlalose, 199 I). 
In rural communities where modern health care facilities are often lacking, traditional 
herbal medicines are commonly used. Plants are identified and harvested from the wild in 
these rural communities, but in urban communities these herbs are purchased from 
herbalists, traditional healers, herbal medicine shops and street vendors (Mabina and 
Moodley, 1997). The results from a 1996 study (Efuntoye) showed that the prolonged 
storage of herbal plant extracts for sale in herbal markets led to fungal growth on a large 
scale. These plants are usually stored in warm humid conditions and are usually stock-
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piled in heaps one on top of the other, thus creating favourable microenvironments which 
enhance microbial growth and activities. This same study revealed F moni/iforme, a 
producer of FB 1 , to be one of the dominant fungal species to be associated with herbal 
drug plants during storage. 
Certain childhood disorders such as malnutrition, congenital malformations, and even 
tumours, may be due to toxic or carcinogenic constituents present in these herbal 
medicines taken during pregnancy. In addition, deaths from acute renal failure, ruptured 
uteri and fatal oesophageal strictures have been attributed to the use of herbal medicine 
(Mabina and Moodley, 1997). There are varying ingredients for this herbal remedy and the 
recipes are usually a closely guarded secret. As a result it is difficult to ascertain whether 
the disorders associated with these herbal remedies are as a result of the herbal ingredients 
themselves, or perhaps due to associated fungal toxins such as FB 1 . The actual preparation 
of these decoctions usually involves boiling the herbal plants. Fumonisin B 1 is a strongly 
polar compound that is soluble in water. As a result any FB 1 contaminating the herbal 
ingredients will be present in the final liquid mixture. Patients with pre-eclampsia may not 
be able to cope with the increased xenobiotic load introduced in the broth due to the 
general organ damage and dysfunction caused by the disease. 
Unfortunately there is no legislation at present that limits the amount of FB 1 that may be 
present in food commodities. Previous investigations have shown the presence of FB 1 in 
commercially available South African food products (Sydenham et al., 1991). This is an 
indication that both rural and urban South African populations are exposed to varying 
levels of FB 1 on a daily basis, on consumption of these products. In addition, many rural 
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and urban black African women may be further exposed to FB 1 via the use of herbal 
medicines during pregnancy. 
Further investigation is required to determine the role of FB 1 in pre-eclampsia and the 
biochemical mechanism by which this mycotoxin delivers its toxic effects. An 
investigation into the use of isihlambezo during pregnancy and the incidence of pre­
eclampsia in these women would provide further evidence of the possible role that FB 1 
plays in this disease. 
In addition the ratio of Sa: So must be studied in normal pregnancy and in pre-eclampsia. 
This was not attempted in this study due to the limited amount of blood (5ml) that could 
be removed from distressed patients in the final stages of labour. In addition these patients 
were talcing part in various studies by other groups and blood samples were not readily 
available. The amount of blood that was obtained was sufficient for the analysis of FB 1 
only. The methods that are currently available for the determination of the Sa:So ratio 
would have to be optimised which would require more than 5ml of blood. 
Although a detailed questionnaire on the dietary habits and the use of isihlambezo among 
the patients admitted to the Labour Ward was not used in this study, patients gave a verbal 
indication that maize was a staple ingredient in their diet. A thorough investigation into the 
dietary habits and prevalence of pre-eclampsia among other racial groups in South Africa 
is also necessary  
The oft repeated saying, "prevention is better than cure" is certainly relevant in South 
Africa where many communities lack modern health care facilities. Opportunities for 
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prevention of fumonisin-induced diseases include reducing exposure and interfering with 
the toxicological processes through nutritional intervention. This requires education at a 
grass roots level. In order to educate people it is necessary to determine the exact 
association between exposure and disease, establishing reliable and reproducible 
indicators of fumonisin exposure and establishing a scientific basis for regulatory 
guidelines to protect the population from the health hazards that are associated with 
exposure to fumonisins. Fumonisins are a human health hazard and continuous exposure 
to even small amounts could be detrimental. 
While the condition of all forms of life is of concern, the ultimate effect of environmental 
degradation is on human health and in this regard, it should be our intention to serve both 
the scientific and the medical communities. Environmentally related diseases are a reality 
of everyday life for practicing physicians and in order that they might be rendered more 
aware of current problems, it is essential that we remain dedicated to the examination and 
evaluation of environmentally induced disease. 
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Information given to subjects 
We would like to remove a small piece of tissue from your placenta/afterbirth after you have 
given birth. This tissue will be used to test for the possible presence of toxins that you may 
have consumed that are present in the food that you eat. 
We would also like a small sample of cord blood (5ml) and maternal blood (5ml). The 
removal of placental tissue and blood will not cause pain or harm to you or your baby. You 
have the right to refuse us permission to remove this tissue and blood sample, or you may 
withdraw your consent at any time. This will not interfere with your treatment. Your 
participation will be greatly appreciated. 
ZULU TRANSLATION 
Uewaningo selukhombisile ukudla esikudlayo kunga nobuthi, yingakho sizocela uphisana 
womzanyana wakho emva kokuba usubelethe. Lesisicubu sizosetshenziswa ekucwaningeni 
kobuthi okungenzeka ukuthi ubudilile obutholakala ekudleni okudlayo. Sizophinda sicele 1-
sampulana legazi lenongwana (5ml). Ukususwa kophisana womzanyana negazi angeke 
kukubangele ubuhlungu, noma kulimaze wena noma ingane yakho. Unalo ilungelo 
lokusinqabela imvume yokususa lesisicubu nesampula legazi, futhi ungasihoxisa nanoma 
yinini isivumelwano sakho. Lokhu akuzukuphazamisa ukwelashwa kwakho ngodokotela. 
Ukuzimbandakanya kwakho kuyoncomeka kakhulu. 






Preparation of 0.5M Tris stock solution 
Dissolved 60.6g Tris-(hydroxymethyl)-aminomethan (molecular weight  121.14) in 800ml 
distilled water. Adjusted pH to 7.2 with concentrated HCI (~40ml) and then adjusted the final 
volume to I 000ml. 
Preparation of0.05M (50mM) Tris-HCI buffer 
Diluted 0.5M Tris stock solution I: 10 with 0.85% physiological saline (0.15M NaCl) 
(i.e., 8. 764g NaCl in l 000ml distilled water). 
Preparation of 1 % BSA in TBS 
Dissolved 0.2g BSA in 15ml 0.05M Tris. Adjusted pH to 8.2 with IM NaOH. 
The volume was made up to 20ml with 0.05M Tris. 
APPENDIX 5.1 
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Preparation of O. lM di-sodium tetraborate buffer 
Dissolved 3 .8g di-sodium tetraborate (molecular weight: 381.36) in 90ml distilled water. 
Adjusted the pH to 10.5 with IM NaOH. 
The volume was made up to 100ml using distilled water. 
APPENDIX 5.3 
Preparation of 0.lM sodium dihydrogenphosphate buffer 
Dissolved 15.6g sodium dihydrogenphosphate (molecular weight: 156.01) in 900ml 
de-ionised water. Adjusted the pH to 3.3 with orthophosphoric acid. 
The volume was made up to 1000ml using de-ionised water. 
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